<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

Nodify Lung Nodule Risk Assessment


nodify-xl2-sm

Nodify XL2® testing helps identify patients with likely benign lung nodules and supports clinical decision-making so physicians can more confidently identify patients who have a reduced risk of malignancy and may avoid unnecessary invasive procedures.

Learn more about:

NODIFY LUNG TESTING STRATEGY

NODIFY CDT TEST

What does the Nodify XL2 test measure and how does it work?

 

Who is eligible for Nodify XL2 testing?

The Nodify XL2 test is intended for patients with incidental lung nodules:

DOWNLOAD THE NODIFY XL2 TEST RESULT REPORT

Clinically Validated Results

  • The Nodify XL2 test measures two proteins associated with an inflammatory response to lung cancer to help physicians identify nodules that are likely benign2.
  • In the PANOPTIC study2, Nodify XL2 demonstrated a median test performance of 97% sensitivity with a 98% negative predictive value (NPV).

READ THE PANOPTIC PUBLICATION
READ THE PANOPTIC EDITORIAL

There is no out of pocket expense for Medicaid and covered Medicare patients for Nodify XL testing

Learn more About our reimbursement

Interested in ordering Nodify Lung testing?

The Nodify Lung Blood Specimen Collection Kit is used for both the Nodify CDT and the Nodify XL2 proteomic tests.

DOWNLOAD OUR INFORMATIONAL BROCHURE
ORDER NODIFY LUNG TESTING
CONTACT OUR TEAM

Get in touch

Contact Us

Data library

Discover More

1. Swensen SJ, Silverstein MD, Ilstrup DM, et. al. "The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules." Arch Intern Med. 1997 Apr 28; 157(8):849-55.

2. Silvestri G et al. "Assessment of plasma proteomics biomarkers ability to distinguish benign from malignant lung nodules." CHEST. 2018 Sept. 154(3):491-500.